Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials.

Moon S, Lee J, Chung HS, Kim YJ, Yu JM, Yu SH, Oh CM

Endocrinology and metabolism (Seoul, Korea)18 Jun 2021Cited by 25 (Europe PMC)

PMID34139800PMCIDPMC8258332DOI10.3803/enm.2020.934PepBankPUB-34139800

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In overweight and obese people, liraglutide reduced body weight compared with placebo, with a mean difference of -4.19 kg.
In plain wordsIn overweight and obese people, liraglutide lowered body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 8,060
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−4.19 kg
liraglutide vs placebo
Change from baseline
−4.16%
liraglutide vs placebo
Source sentences
Summary
The mean difference (MD) between the liraglutide group and the placebo group was -4.19 kg (95% confidence interval [CI], -4.84 to -3.55), with a -4.16% change from the baseline (95% CI, -4.90 to -3.43).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Summary · context
We included 31 studies with 8,060 participants for this meta-analysis.
Report a problemFND-3413980001
02HumanSystematic reviewEfficacy outcome
In overweight and obese people, liraglutide significantly reduced body mass index compared with placebo.
In plain wordsIn overweight and obese people, liraglutide lowered BMI more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−1.55 NA
BMI
Source sentences
Summary
Liraglutide treatment correlated with a significantly reduced body mass index (MD: -1.55; 95% CI, -1.76 to -1.34)
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Summary · context
We included 31 studies with 8,060 participants for this meta-analysis.
Report a problemFND-3413980002
03HumanSystematic reviewEfficacy outcome
In overweight and obese people, liraglutide significantly reduced waist circumference compared with placebo.
In plain wordsIn overweight and obese people, liraglutide reduced waist size more than placebo.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−3.11 cm
waist circumference
Source sentences
Summary
waist circumference (MD: -3.11 cm; 95% CI, -3.59 to -2.62)
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Summary · context
We included 31 studies with 8,060 participants for this meta-analysis.
Report a problemFND-3413980003
04HumanSystematic reviewEfficacy outcome
In overweight and obese people, liraglutide significantly decreased systolic blood pressure compared with placebo.
In plain wordsIn overweight and obese people, liraglutide lowered systolic blood pressure more than placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
MD
−2.85 mm Hg
systolic blood pressure
Source sentences
Summary
systolic blood pressure, MD: -2.85 mm Hg; 95% CI, -3.36 to -2.35
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Summary · context
We included 31 studies with 8,060 participants for this meta-analysis.
Report a problemFND-3413980004
05HumanSystematic reviewEfficacy outcome
In overweight and obese people, liraglutide significantly decreased diastolic blood pressure compared with placebo.
In plain wordsIn overweight and obese people, liraglutide lowered diastolic blood pressure more than placebo.
Peptide
Liraglutide
Outcome
DecreaseDiastolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
MD
−0.66 mm Hg
diastolic blood pressure
Source sentences
Summary
diastolic blood pressure, MD: -0.66 mm Hg; 95% CI, -1.02 to -0.30
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Summary · context
We included 31 studies with 8,060 participants for this meta-analysis.
Report a problemFND-3413980005
06HumanSystematic reviewEfficacy outcome
In overweight and obese people, liraglutide significantly decreased glycated hemoglobin compared with placebo.
In plain wordsIn overweight and obese people, liraglutide lowered glycated hemoglobin, a long-term blood sugar marker, more than placebo.
Peptide
Liraglutide
Outcome
DecreaseGlycated hemoglobin
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−0.4%
HbA1c
Source sentences
Summary
glycated hemoglobin (MD: -0.40%; 95% CI, -0.49 to -0.31)
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Summary · context
We included 31 studies with 8,060 participants for this meta-analysis.
Report a problemFND-3413980006
07HumanSystematic reviewEfficacy outcome
In overweight and obese people, liraglutide significantly decreased LDL cholesterol compared with placebo.
In plain wordsIn overweight and obese people, liraglutide lowered LDL (bad) cholesterol more than placebo.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Measurements
MD
−2.91 mg/dL
LDL cholesterol
MD change from baseline
−0.87%
LDL cholesterol
Source sentences
Summary
low-density lipoprotein cholesterol (MD: -2.91 mg/dL; 95% CI, -5.28 to -0.53; MD: -0.87% change from baseline; 95% CI, -1.17 to -0.56)
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Summary · context
We included 31 studies with 8,060 participants for this meta-analysis.
Report a problemFND-3413980007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.